Published in ACS Chem Neurosci on April 11, 2011
Biophysical insights into how surfaces, including lipid membranes, modulate protein aggregation related to neurodegeneration. Front Neurol (2013) 0.96
The modulating effect of mechanical changes in lipid bilayers caused by apoE-containing lipoproteins on Aβ induced membrane disruption. ACS Chem Neurosci (2011) 0.78
Cholesterol Modifies Huntingtin Binding to, Disruption of, and Aggregation on Lipid Membranes. Biochemistry (2015) 0.75
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol (2007) 17.69
A specific amyloid-beta protein assembly in the brain impairs memory. Nature (2006) 16.19
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A (1998) 16.04
Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci (2004) 9.73
Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science (2005) 8.86
Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol (2004) 7.02
Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem (2002) 5.63
Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A (2002) 5.46
The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci (2001) 5.29
Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem (1997) 5.07
Molecular structural basis for polymorphism in Alzheimer's beta-amyloid fibrils. Proc Natl Acad Sci U S A (2008) 4.84
In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem (2002) 4.20
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem (2007) 3.42
Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem (2007) 3.13
From the globular to the fibrous state: protein structure and structural conversion in amyloid formation. Q Rev Biophys (1998) 3.04
Amyloid beta-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J Biol Chem (2001) 2.77
Polymorphism in the intermediates and products of amyloid assembly. Curr Opin Struct Biol (2007) 2.75
In situ atomic force microscopy study of Alzheimer's beta-amyloid peptide on different substrates: new insights into mechanism of beta-sheet formation. Proc Natl Acad Sci U S A (1999) 2.24
Studies on the in vitro assembly of a beta 1-40: implications for the search for a beta fibril formation inhibitors. J Struct Biol (2000) 2.19
Seeded growth of beta-amyloid fibrils from Alzheimer's brain-derived fibrils produces a distinct fibril structure. Proc Natl Acad Sci U S A (2009) 2.15
The interaction of proteins with solid surfaces. Curr Opin Struct Biol (2004) 1.96
Abeta(1-40) fibril polymorphism implies diverse interaction patterns in amyloid fibrils. J Mol Biol (2008) 1.86
Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. J Mol Biol (2003) 1.81
Pathogenic effects of D23N Iowa mutant amyloid beta -protein. J Biol Chem (2001) 1.74
Abeta(1-40) forms five distinct amyloid structures whose beta-sheet contents and fibril stabilities are correlated. J Mol Biol (2010) 1.74
Substitutions at codon 22 of Alzheimer's abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. J Biol Chem (2000) 1.71
Neurotoxicity and physicochemical properties of Abeta mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease. J Biol Chem (2003) 1.53
Differences between the pathogenesis of senile plaques and congophilic angiopathy in Alzheimer disease. J Neuropathol Exp Neurol (1997) 1.46
In-situ atomic force microscopy study of beta-amyloid fibrillization. J Mol Biol (2000) 1.40
Flemish and Dutch mutations in amyloid beta precursor protein have different effects on amyloid beta secretion. Neurobiol Dis (1998) 1.24
Amyloid-beta membrane binding and permeabilization are distinct processes influenced separately by membrane charge and fluidity. J Mol Biol (2008) 1.22
Synthesis, aggregation, neurotoxicity, and secondary structure of various A beta 1-42 mutants of familial Alzheimer's disease at positions 21-23. Biochem Biophys Res Commun (2002) 1.20
Similarities in the thermodynamics and kinetics of aggregation of disease-related Abeta(1-40) peptides. Protein Sci (2007) 1.16
Physiochemical characterization of the Alzheimer's disease-related peptides A beta 1-42Arctic and A beta 1-42wt. FEBS J (2006) 1.14
Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. J Mol Biol (2004) 1.08
In vitro studies of amyloid beta-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692-->Gly) Alzheimer's disease. Biochem J (2001) 1.06
Oligomerization of beta-amyloid of the Alzheimer's and the Dutch-cerebral-haemorrhage types. Biochem J (2000) 1.05
Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry (2004) 1.01
Aggregation and metal-binding properties of mutant forms of the amyloid A beta peptide of Alzheimer's disease. J Neurochem (1996) 0.97
Effects of the mutations Glu22 to Gln and Ala21 to Gly on the aggregation of a synthetic fragment of the Alzheimer's amyloid beta/A4 peptide. Neurosci Lett (1993) 0.97
Effects of the amyloid precursor protein Glu693-->Gln 'Dutch' mutation on the production and stability of amyloid beta-protein. Biochem J (1999) 0.95
Amyloid toxicity is independent of polypeptide sequence, length and chirality. J Mol Biol (2007) 0.95
Monoclonal antibody against the turn of the 42-residue amyloid β-protein at positions 22 and 23. ACS Chem Neurosci (2010) 0.92
Comparison of the aggregation properties, secondary structure and apoptotic effects of wild-type, Flemish and Dutch N-terminally truncated amyloid beta peptides. Eur J Neurosci (2001) 0.92
The turn formation at positions 22 and 23 in the 42-mer amyloid beta peptide: the emerging role in the pathogenesis of Alzheimer's disease. Geriatr Gerontol Int (2010) 0.87
Single chain Fv antibodies against the 25-35 Abeta fragment inhibit aggregation and toxicity of Abeta42. Biochemistry (2006) 0.86
Autoinsertion of soluble oligomers of Alzheimer's Abeta(1-42) peptide into cholesterol-containing membranes is accompanied by relocation of the sterol towards the bilayer surface. BMC Struct Biol (2006) 0.84
Point mutations in Aβ result in the formation of distinct polymorphic aggregates in the presence of lipid bilayers. PLoS One (2011) 0.84
The Arctic Alzheimer mutation enhances sensitivity to toxic stress in human neuroblastoma cells. Neurosci Lett (2002) 0.77
Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem (2007) 3.13
Structure of gel phase DMPC determined by X-ray diffraction. Biophys J (2002) 2.65
Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat Chem Biol (2011) 2.24
ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem (2004) 2.19
Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum Mol Genet (2006) 1.77
Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease. Hum Mol Genet (2010) 1.71
Collagen VI protects neurons against Abeta toxicity. Nat Neurosci (2009) 1.19
Identification of novel potentially toxic oligomers formed in vitro from mammalian-derived expanded huntingtin exon-1 protein. J Biol Chem (2012) 1.07
Hsp70 and Hsp40 functionally interact with soluble mutant huntingtin oligomers in a classic ATP-dependent reaction cycle. J Biol Chem (2010) 1.01
Biophysical insights into how surfaces, including lipid membranes, modulate protein aggregation related to neurodegeneration. Front Neurol (2013) 0.96
The interaction of polyglutamine peptides with lipid membranes is regulated by flanking sequences associated with huntingtin. J Biol Chem (2013) 0.94
Assessing mutant huntingtin fragment and polyglutamine aggregation by atomic force microscopy. Methods (2010) 0.88
Amyloid-forming proteins alter the local mechanical properties of lipid membranes. Biochemistry (2013) 0.88
The role of amyloidogenic protein oligomerization in neurodegenerative disease. J Mol Med (Berl) (2013) 0.85
Huntingtin disrupts lipid bilayers in a polyQ-length dependent manner. Biochim Biophys Acta (2013) 0.84
Point mutations in Aβ result in the formation of distinct polymorphic aggregates in the presence of lipid bilayers. PLoS One (2011) 0.84
Specific domains of Aβ facilitate aggregation on and association with lipid bilayers. J Mol Biol (2013) 0.81
Lysine residues in the N-terminal huntingtin amphipathic α-helix play a key role in peptide aggregation. J Mass Spectrom (2015) 0.80
Curvature enhances binding and aggregation of huntingtin at lipid membranes. Biochemistry (2014) 0.80
Mapping the mechanical properties of cholesterol-containing supported lipid bilayers with nanoscale spatial resolution. Langmuir (2012) 0.78
The emerging role of the first 17 amino acids of huntingtin in Huntington's disease. Biomol Concepts (2015) 0.76
Preparation protocols of aβ(1-40) promote the formation of polymorphic aggregates and altered interactions with lipid bilayers. Biochemistry (2014) 0.76
Investigation of temperature induced mechanical changes in supported bilayers by variants of tapping mode atomic force microscopy. Scanning (2014) 0.76
Atomic force microscopy assays for evaluating polyglutamine aggregation in solution and on surfaces. Methods Mol Biol (2013) 0.75